EHA Library - The official digital education library of European Hematology Association (EHA)

WHICH ORGAN SHOULD WE BIOPSY TO DIAGNOSE AL AMYLOIDOSIS ?
Author(s): ,
Laura Llorente Gonzalez
Affiliations:
Hematology,Hospital Universitario Puerta de Hierro de Majadahonda,Majadahonda,Spain
,
Carlos de Miguel Jiménez
Affiliations:
Hematology,Hospital Universitario Puerta de Hierro de Majadahonda,Majadahonda,Spain
,
Clara Salas
Affiliations:
Anatomical Pathology,Hospital Universitario Puerta de Hierro de Majadahonda,Majadahonda,Spain
,
Pablo García-Pavía
Affiliations:
Cardiology,Hospital Universitario Puerta de Hierro de Majadahonda,Majadahonda,Spain
,
Esther Gonzalez
Affiliations:
Cardiology,Hospital Universitario Puerta de Hierro de Majadahonda,Majadahonda,Spain
,
Juan Antonio López del Olmo
Affiliations:
Cardiovascular Proteomics,Centro Nacional de Investigaciones Cardiovasculares Carlos III,Majadahonda,Spain
,
Jesús María Vazquez Cobos
Affiliations:
Cardiovascular Proteomics,Centro Nacional de Investigaciones Cardiovasculares Carlos III,Majadahonda,Spain
Isabel Krsnik
Affiliations:
Hematology,Hospital Universitario Puerta de Hierro de Majadahonda,Majadahonda,Spain
(Abstract release date: 05/18/17) EHA Library. Llorente L. 05/18/17; 182711; PB1997
Laura Llorente
Laura Llorente
Contributions
Abstract

Abstract: PB1997

Type: Publication Only

Background

Light chain (AL) amyloidosis is a deposition disease with can affect many organs and with a variable but usually bad, prognosis. Therapy requires a quick and correct diagnosis. Accurate identification of amyloid deposition and of the amyloid subtype in tissue biopsies is thus, mandatory. Random biopsies of easily accessible tissues such as subcutaneous fat, gingivae or rectum are usually recommended but sensitivity of this approach is low.

Aims
To present our experience with tissue biopsies performed in 62 consecutive patients diagnosed of AL amyloidosis in our center.

Methods

We reviewed all tissue biopsies performed during the study period (2004-2017) in 62 consecutive patients diagnosed of AL amyloidosis at the same center. A bone marrow (BM) biopsy was performed per protocol in all cases. Decisions on biopsies were taken considering organ involvement and accessibility: skin, lymph nodes, lung or tongue biopsies were performed when lesions were seen on clinical or X-ray examinations, cardiac biopsies in the presence of increased NT-proBNP (N-terminal natriuretic peptide) levels and typical echocardiographic findings, kidney biopsies in patients with nephrotic syndromes. Biopsies were stained with Congo Red and read under polarized light with a Texas filter. Subtyping of the amyloid was done using anti-kappa, anti-lambda, anti-TTR and anti-A antisera.
If any biopsy was positive for AL amyloid, no further biopsies were performed unless necessary for therapeutic decisions.

Results
A total of 152 biopsies were performed during the study period: see table

Tissue
Biopsies
AL amyloidosis
Bone marrow
59
25 (42.2%)
Heart
37
33 (89.2%)
Kidney
8
8 (100%)
Intestine/Rectum/ Stomach
10
7 (70%)
Gingivae
13
4 (30.7%)
Subcutaneous fat
11
4 (36.4%)
Liver
2
2 (100%)
Skin
2
2 (100%)
Tongue
3
3 (100%)
Lung
2
2 (100%)
Sural nerve
3
3 (100%)
Lymphnode
1
1 (100%)
Tonsil
1
1 (100%)
Total of biopsies
152
95 (94.7%)

Conclusion

Prognosis in AL amyloidosis is slowly improving with the use of new anti-myeloma drugs and may improve further with new monoclonal antibodies. Therapy requires an early and accurate diagnosis. We do not perform random biopsies of tissues such as fat or gingivae due to low sensitivity. In our hands biopsies of tissues or organs with clinical, analytical or radiological involvement shows higher sensitivity. A bone marrow biopsy is required for diagnosis of the neoplastic disease underlying AL amyloidosis and may show amyloid in up to 50% of the cases. Cardiac biopsy is also highly sensitive and in centers with a high degree of expertise such as ours, has no complications. Our data allow us to recommend a different approach to AL amyloidosis of what is usually published. Biopsies of clinically involved organs yields almost 100% sensitivity. Random biopsies of gingivae, subcutaneous fat or rectum should be discouraged.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): AL amyloidosis

Abstract: PB1997

Type: Publication Only

Background

Light chain (AL) amyloidosis is a deposition disease with can affect many organs and with a variable but usually bad, prognosis. Therapy requires a quick and correct diagnosis. Accurate identification of amyloid deposition and of the amyloid subtype in tissue biopsies is thus, mandatory. Random biopsies of easily accessible tissues such as subcutaneous fat, gingivae or rectum are usually recommended but sensitivity of this approach is low.

Aims
To present our experience with tissue biopsies performed in 62 consecutive patients diagnosed of AL amyloidosis in our center.

Methods

We reviewed all tissue biopsies performed during the study period (2004-2017) in 62 consecutive patients diagnosed of AL amyloidosis at the same center. A bone marrow (BM) biopsy was performed per protocol in all cases. Decisions on biopsies were taken considering organ involvement and accessibility: skin, lymph nodes, lung or tongue biopsies were performed when lesions were seen on clinical or X-ray examinations, cardiac biopsies in the presence of increased NT-proBNP (N-terminal natriuretic peptide) levels and typical echocardiographic findings, kidney biopsies in patients with nephrotic syndromes. Biopsies were stained with Congo Red and read under polarized light with a Texas filter. Subtyping of the amyloid was done using anti-kappa, anti-lambda, anti-TTR and anti-A antisera.
If any biopsy was positive for AL amyloid, no further biopsies were performed unless necessary for therapeutic decisions.

Results
A total of 152 biopsies were performed during the study period: see table

Tissue
Biopsies
AL amyloidosis
Bone marrow
59
25 (42.2%)
Heart
37
33 (89.2%)
Kidney
8
8 (100%)
Intestine/Rectum/ Stomach
10
7 (70%)
Gingivae
13
4 (30.7%)
Subcutaneous fat
11
4 (36.4%)
Liver
2
2 (100%)
Skin
2
2 (100%)
Tongue
3
3 (100%)
Lung
2
2 (100%)
Sural nerve
3
3 (100%)
Lymphnode
1
1 (100%)
Tonsil
1
1 (100%)
Total of biopsies
152
95 (94.7%)

Conclusion

Prognosis in AL amyloidosis is slowly improving with the use of new anti-myeloma drugs and may improve further with new monoclonal antibodies. Therapy requires an early and accurate diagnosis. We do not perform random biopsies of tissues such as fat or gingivae due to low sensitivity. In our hands biopsies of tissues or organs with clinical, analytical or radiological involvement shows higher sensitivity. A bone marrow biopsy is required for diagnosis of the neoplastic disease underlying AL amyloidosis and may show amyloid in up to 50% of the cases. Cardiac biopsy is also highly sensitive and in centers with a high degree of expertise such as ours, has no complications. Our data allow us to recommend a different approach to AL amyloidosis of what is usually published. Biopsies of clinically involved organs yields almost 100% sensitivity. Random biopsies of gingivae, subcutaneous fat or rectum should be discouraged.

Session topic: 14. Myeloma and other monoclonal gammopathies - Clinical

Keyword(s): AL amyloidosis

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies